{"nct_id":"NCT02787551","title":"Efficacy and Safety of the Insulin Glargine/Lixisenatide Fixed Ratio Combination (FRC) Versus GLP-1 Receptor Agonist in Patients With Type 2 Diabetes, With a FRC Extension Period","status":"COMPLETED","status_verified_date":"2022-03","start_date":"2016-07-06","start_date_type":"ACTUAL","primary_completion_date":"2018-05-25","primary_completion_date_type":"ACTUAL","completion_date":"2018-11-17","completion_date_type":"ACTUAL","phases":["PHASE3"],"tickers":["SNY"]}